近期论文

查看导师最新文章 （温馨提示：请注意重名现象，建议点开原文通过作者单位确认）

Meehan, J, Ward, C, Turnbull, A, Bukowski-Wills, J, Finch, A, Jarman, EJ, Xintaropoulou, C, Martinez-Perez, C, Gray, M, Pearson, M, Mullen, P, Supuran, CT, Carta, F, Harrison, DJ, Kunkler, IH & Langdon, S 2017, 'Inhibition of pH regulation as a therapeutic strategy in hypoxic human breast cancer cells' Oncotarget. Wilkie, RP, Neal, A, Johnston, CA, Vo?te, N, Lancefield, CS, Stell, M, Medda, F, Makiyi, EF, Turner, E, Ojo, OS, Slawin, AMZ, Lebl, T, Mullen, P, Harrison, DJ, Ireland, CM & Westwood, NJ 2016, 'Total synthesis of dehaloperophoramidine using a highly diastereoselective Hosomi-Sakurai reaction' Chemical Communications, vol 52, no. 71, pp. 10747-10750. DOI: 10.1039/c6cc05747k Brown, JL, Shovman, M, Robertson, P, Boiko, A, Goltsov, A, Mullen, P & Harrison, DJ 2016, 'A signaling visualization toolkit to support rational design of combination therapies and biomarker discovery: SiViT' Oncotarget, vol Advance Publication. DOI: 10.18632/oncotarget.8747 Martínez-Pérez, C, Ward, C, Turnbull, AK, Mullen, P, Cook, G, Meehan, J, Jarman, EJ, Thomson, PIT, Campbell, CJ, McPhail, D, Harrison, DJ & Langdon, SP 2016, 'Antitumour activity of the novel flavonoid oncamex in preclinical breast cancer models' British Journal of Cancer, vol 114, no. 8, pp. 905-916. DOI: 10.1038/bjc.2016.6 Huang, R, Langdon, SP, Tse, M, Mullen, P, Um, IH, Faratian, D & Harrison, DJ 2015, 'The role of HDAC2 in chromatin remodelling and response to chemotherapy in ovarian cancer' Oncotarget, vol 7, no. 4, pp. 4695-4711. DOI: 10.18632/oncotarget.6618 Riches, AC, Powis, SJ, Mullen, P, Harrison, DJ, Hacker, C, Lucocq, JM, Bowness, JS, Chapman, A, Cameron, R, McLornan, L, Chinn, DJ & Leung, S 2015, 'Human urinary exosomes in bladder cancer patients: properties, concentrations and possible clinical application' Bladder, vol 2, no. 3, e19. DOI: 10.14440/bladder.0.63 Stewart, GD, O'Mahony, F, Laird, A, Eory, L, Lubbock, A, Mackay, A, Nanda, J, O'Donnell, M, Mullen, P, McNeill, A, Riddick, A, Berney, D, Bex, A, Aitchison, M, Overton, IM, Harrison, DJ & Powles, T 2015, 'Sunitinib treatment exacerbates intratumoral heterogeneity in metastatic renal cancer' Clinical Cancer Research, vol In press. DOI: 10.1158/1078-0432.CCR-15-0207 Ward, C, Meehan, J, Mullen, P, Supuran, C, Dixon, JM, Thomas, JS, Winum, J-Y, Lambin, P, Dubois, L, Pavathaneni, N-K, Jarman, EJ, Renshaw, L, Um, IH, Kay, C, Harrison, DJ, Kunkler, IH & Langdon, SP 2015, 'Evaluation of carbonic anhydrase IX as a therapeutic target for inhibition of breast cancer invasion and metastasis using a series of in vitro breast cancer models' Oncotarget, vol 6, no. 28, pp. 24865-24870. Stewart, GD, O'Mahony, FC, Laird, A, Rashid, S, Martin, SA, Eory, L, Lubbock, ALR, Nanda, J, O'Donnell, M, Mackay, A, Mullen, P, McNeill, SA, Riddick, ACP, Aitchison, M, Berney, D, Bex, A, Overton, IM, Harrison, DJ & Powles, T 2014, 'Carbonic anhydrase 9 expression increases with vascular endothelial growth factor-targeted therapy and is predictive of outcome in metastatic clear cell renal cancer' European Urology, vol 66, no. 5, pp. 956-963. DOI: 10.1016/j.eururo.2014.04.007 Martinez-Perez, C, Ward, C, Cook, G, Mullen, P, D, M, Harrison, D & Langdon, S 2014, 'Novel flavonoids as anti-cancer agents: mechanisms of action and promise for their potential application in breast cancer.' Biochemical Society Transactions, vol 42, no. 4, pp. 1017-1023. DOI: 10.1042/BST20140073 Stewart, G, Laird, A, O'Mahony, F, Eory, L, Lubbock, A, Nanda, J, O'Donnell, M, Mackay, A, Mullen, P, McNeill, A, Riddick, A, Aitchison, M, Berney, D, Bex, A, Overton, I, Harrison, DJ & Powles, T 2014, 'The effect of sunitinib on biomarkers and tumor heterogeneity in metastatic clear cell renal cancer.' Journal of Clinical Oncology, vol 32, no. 4. Caie, PD, Schuur, K, Oniscu, A, Mullen, P, Reynolds, PA & Harrison, DJ 2013, 'Human tissue in systems medicine' FEBS Journal, vol 280, no. 23, pp. 5949–5956. DOI: 10.1111/febs.12550 Tashkandi, G, Mullen, P, Goltsov, A, Bown, JL, Harrison, DJ & Langdon, SP 2013, 'Use of reverse phase protein arrays to identify biomarkers of response to PI3K/mTOR inhibitors in ovarian cancer models' Journal of Pathology, vol 231, pp. 25. Francis, KE, Mullen, P, Um, I, Kay, C, Harrison, DJ & Langdon, SP 2013, 'Characterisation of phosphorylated checkpoint kinase 1 as a poor prognostic biomarker in serous ovarian cancer' Journal of Pathology, vol 231, pp. 46. Ward, C, Langdon, SP, Mullen, P, Harris, AL, Harrison, DJ, Supuran, CT & Kunkler, I 2013, 'New strategies for targeting the hypoxic tumour microenvironment in breast cancer' Cancer Treatment Reviews, vol 39, no. 2, pp. 171-179. DOI: 10.1016/j.ctrv.2012.08.004 O'Mahony, FC, Nanda, J, Laird, A, Mullen, P, Caldwell, H, Overton, IM, Eory, L, O'Donnell, M, Faratian, D, Powles, T, Harrison, DJ & Stewart, GD 2013, 'The use of reverse phase protein arrays (RPPA) to explore protein expression variation within individual renal cell cancers' Journal of Visualized Experiments, no. 71. DOI: 10.3791/50221 Lebedeva, G, Sorokin, A, Faratian, D, Mullen, P, Goltsov, A, Langdon, SP, Harrison, DJ & Goryanin, I 2012, 'Model-based global sensitivity analysis as applied to identification of anti-cancer drug targets and biomarkers of drug resistance in the ErbB2/3 network' European Journal of Pharmaceutical Sciences, vol 46, no. 4, pp. 244-258. DOI: 10.1016/j.ejps.2011.10.026 Winum, J-Y, Carta, F, Ward, C, Mullen, P, Harrison, D, Langdon, SP, Cecchi, A, Scozzafava, A, Kunkler, I & Supuran, CT 2012, 'Ureido-substituted sulfamates show potent carbonic anhydrase IX inhibitory and antiproliferative activities against breast cancer cell lines' Bioorganic and Medicinal Chemistry Letters, vol 22, no. 14, pp. 4681-4685. DOI: 10.1016/j.bmcl.2012.05.083 Welman, A, Sproul, D, Mullen, P, Muir, M, Kinnaird, AR, Harrison, DJ, Faratian, D, Brunton, VG & Frame, MC 2012, 'Diversity of matriptase expression level and function in breast cancer' PLoS One, vol 7, no. 4, e34182. DOI: 10.1371/journal.pone.0034182 Goltsov, A, Faratian, D, Langdon, SP, Mullen, P, Harrison, DJ & Bown, J 2012, 'Features of the reversible sensitivity-resistance transition in PI3K/PTEN/AKT signalling network after HER2 inhibition' Cellular Signalling, vol 24, no. 2, pp. 493-504. DOI: 10.1016/j.cellsig.2011.09.030 Faratian, D, Sims, AH, Mullen, P, Kay, C, Um, I, Langdon, SP & Harrison, DJ 2011, 'Sprouty 2 is an independent prognostic factor in breast cancer and may be useful in stratifying patients for trastuzumab therapy' PLoS One, vol 6, no. 8, e23772, pp. -. DOI: 10.1371/journal.pone.0023772 Faratian, D, Zweemer, AJM, Nagumo, Y, Sims, AH, Muir, M, Dodds, M, Mullen, P, Um, I, Kay, C, Hasmann, M, Harrison, DJ & Langdon, SP 2011, 'Trastuzumab and Pertuzumab produce changes in morphology and estrogen receptor signaling in ovarian cancer xenografts revealing new treatment strategies' Clinical Cancer Research, vol 17, no. 13, pp. 4451-4461. DOI: 10.1158/1078-0432.CCR-10-2461 Faratian, D, Um, I, Wilson, DS, Mullen, P, Langdon, SP & Harrison, DJ 2011, 'Phosphoprotein pathway profiling of ovarian carcinoma for the identification of potential new targets for therapy' European Journal of Cancer, vol 47, no. 9, pp. 1420-1431. DOI: 10.1016/j.ejca.2011.01.014 Hochgraefe, F, Zhang, L, O'Toole, SA, Browne, BC, Pinese, M, Cubas, AP, Lehrbach, GM, Croucher, DR, Rickwood, D, Boulghourjian, A, Shearer, R, Nair, R, Swarbrick, A, Faratian, D, Mullen, P, Harrison, DJ, Biankin, AV, Sutherland, RL, Raftery, MJ & Daly, RJ 2010, 'Tyrosine phosphorylation profiling reveals the signaling network characteristics of basal breast cancer cells' Cancer Research, vol 70, no. 22, pp. 9391-9401. DOI: 10.1158/0008-5472.CAN-10-0911 Langdon, SP, Faratian, D, Nagumo, Y, Mullen, P & Harrison, DJ 2010, 'Pertuzumab for the treatment of ovarian cancer' Expert Opinion on Biological Therapy, vol 10, no. 7, pp. 1113-1120. DOI: 10.1517/14712598.2010.487062